Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study
- 15 March 2005
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 106 (1), 27-34
- https://doi.org/10.1182/blood-2004-09-3728
Abstract
The role of glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) in the induction treatment of older adults with acute myeloid leukemia (AML) is still uncertain. In this trial, a total of 722 patients with newly diagnosed AML, median age 68 years, were randomized into 4 treatment arms: (A) no G-CSF; (B) G-CSF during chemotherapy; (C) G-CSF after chemotherapy until day 28 or recovery of polymorphonuclear leukocytes; and (D) G-CSF during and after chemotherapy. The complete remission (CR) rate was 48.9% in group A, 52.2% in group B, 48.3% in group C, and 64.4% in group D. Analysis according to the 2 × 2 factorial design indicated that the CR rate was significantly higher in patients who received G-CSF during chemotherapy (58.3% for groups B + D vs 48.6% for groups A + C; P = .009), whereas no significant difference was observed between groups A + B and C + D (50.6% vs 56.4%, P = .12). In terms of overall survival, no significant differences were observed between the various groups. Patients who received G-CSF after chemotherapy had a shorter time to neutrophil recovery (median, 20 vs 25 days; P < .001) and a shorter hospitalization (mean, 27.2 vs 29.7 days; P < .001). We conclude that although priming with G-CSF can improve the CR rate, the use of G-CSF during and/or after chemotherapy has no effect on the long-term outcome of AML in older patients.Keywords
This publication has 41 references indexed in Scilit:
- Priming with Granulocyte Colony-Stimulating Factor — Relation to High-Dose Cytarabine in Acute Myeloid LeukemiaThe New England Journal of Medicine, 2004
- A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology GroupBlood, 2004
- Cost Analyses Of Adjunct Colony Stimulating Factors For Older Patients With Acute Myeloid LeukaemiaDrugs & Aging, 2003
- The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trialBlood, 2001
- TrueLeukemia, 1999
- New Neuromuscular Blocking DrugsThe New England Journal of Medicine, 1995
- A Controlled Study of Recombinant Human Granulocyte Colony-Stimulating Factor in Elderly Patients after Treatment for Acute Myelogenous LeukemiaThe New England Journal of Medicine, 1995
- Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous LeukemiaThe New England Journal of Medicine, 1995
- Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO)British Journal of Haematology, 1991
- Tables of the number of patients required in clinical trials using the logrank testStatistics in Medicine, 1982